Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci

Blood (2016) 128 (22): 4511.

https://doi.org/10.1182/blood.V128.22.4511.4511

Published: 2016

Journal Articles

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Mark B Pepys, MDPhDFRS FMedSci, Louise M Cookson, BSc, Sharon V Barton, BSc MSc, Alienor C Berges, PharmD, Thirusha Lane, RN MSc, David Hutt, BAppSc, Marianna Fontana, MD, James C Moon, MD, Julian D Gillmore, MDPhDFRCP, Ashutosh Wechalekar, MDFRCPath FRCP, Philip N Hawkins, MDPhDFMedSci, Duncan B Richards, DM FRCP

Blood (2015) 126 (23): 1836.

https://doi.org/10.1182/blood.V126.23.1836.1836

Published: 2015

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 2966.

https://doi.org/10.1182/blood.V120.21.2966.2966

Published: 2012

Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2012) 120 (21): 2978.

https://doi.org/10.1182/blood.V120.21.2978.2978

Published: 2012

Journal Articles

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD

Blood (2011) 118 (21): 3975.

https://doi.org/10.1182/blood.V118.21.3975.3975

Published: 2011

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Blood (2011) 118 (21): 3978.

https://doi.org/10.1182/blood.V118.21.3978.3978

Published: 2011

Journal Articles

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Ashutosh Wechalekar, MD, Simon Gibbs, MD, Jennifer Pinney, MD, Christopher P Venner, MD, Sanjay Banypersad, MD, Helen Lachmann, MD, Philip N Hawkins, MD, Julian D Gillmore, MD

Blood (2011) 118 (21): 992.

https://doi.org/10.1182/blood.V118.21.992.992

Published: 2011

Journal Articles

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Ashutosh Wechalekar, MD, Stefan O Schonland, MD, Efstathios Kastritis, Philip N Hawkins, Meletios A. Dimopoulos, Paola Russo, MD, Thirusha Lane, RN, Andrea Foli, MD, Darren Foard, RN, Paolo Milani, MD, Lisa Rannigan, RN, Ute Hegenbart, Julian D Gillmore, Giampaolo Merlini, Giovanni Palladini

Blood (2011) 118 (21): 995.

https://doi.org/10.1182/blood.V118.21.995.995

Published: 2011

NARROW

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only